Article

Apalutamide Monotherapy in Metastatic Hormone-Sensitive Prostate Cancer: a Viable Alternative to First Generation Anti-Androgen Agents to Avoid the Flare Phenomenon and an Effective Treatment to Achieve Early PSA Response

2025-06-25

Abstract excerpt

<h4>Background: </h4> /Objectives. Androgen Deprivation Therapy (ADT) is the mainstay of prostate cancer treatment, especially in the advanced disease. In particular, the Gonadotropin-Releasing Hormone agonists (aGnRH) reduce the production of gonadotropin and, therefore, testosterone. In about 10% of patients, the non-pulsatile stimulation of GnRH receptor initially causes a surge in LH and testosterone, defined...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7ad5f264-61c6-55e2-bfea-b126f0f5743e
DOI: 10.20944/preprints202506.2031.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Apalutamide Monotherapy in Metastatic Hormone-Sensitive Prostate Cancer: a Viable Alternative to First Generation Anti-Androgen Agents to Avoid the Flare Phenomenon and an Effective Treatment to Achieve Early PSA ResponseDOI 10.20944/preprints202506.2031.v1Read

Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysisSemantic proximity Read

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancerSemantic proximity Read

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.Semantic proximity Read

Impact of the COVID-19 Pandemic on Prostate Cancer Diagnosis, Staging, and Treatment: A Population-Based Study in Northern ItalySemantic proximity Read

Use of Antiandrogens as Therapeutic Agents in COVID-19 PatientsSemantic proximity Read

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).Semantic proximity Read

Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.Semantic proximity Read

Structural insights into the mechanism of resistance to bicalutamide by the clinical mutations in androgen receptor in chemo-treatment resistant prostate cancer.Semantic proximity Read

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Semantic proximity Read

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Semantic proximity Read